# Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

> **NCT02722941** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 30 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT02722941
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-10
- **Primary completion:** 2020-06-07
- **Final completion:** 2021-01-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722941, "Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02722941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*